公开(公告)号：US20190040381A1

公开(公告)日：2019-02-07

申请号：US15780938

申请日：2016-12-02

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Paul Thomas ,  Xizhi Guo ,  Pradyot Dash

IPC: C12N15/10 ,  C12N15/66

Abstract: The invention provides a method for rapid cloning of T-cell receptors (TCRs) (e.g., paired αβ and γδ TCR chains) and B-cell receptors (BCRs) (e.g. paired IgH or IgK or Igλ) from single cells by CDR3 substitution using single cell PCR products and Gibson Assembly techniques and a pre-generated TCR (or BCR) library in an expression vector.

公开(公告)号：US20180318331A1

公开(公告)日：2018-11-08

申请号：US15740687

申请日：2016-06-30

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Stanislav S. ZAKHARENKO

IPC: A61K31/713 ,  C12N15/113 ,  A61K9/00

CPC classification number: A61K31/713 ,  A61K9/0043 ,  C12N15/113 ,  C12N15/861 ,  C12N2310/141 ,  C12Q1/6841 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/178 ,  G01N2800/302

Abstract: The invention is directed to a method for treating the 22q11 deletion syndrome (22q11 DS) and schizophrenia (SCZ) by replenishment of decreased levels of miR-338-3p in thalamic neurons.

公开(公告)号：US20180126006A1

公开(公告)日：2018-05-10

申请号：US15573684

申请日：2016-05-13

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

Inventor： John T. GRAY

IPC: A61K48/00 ,  C12N15/861 ,  A61K35/76 ,  C12N7/00

CPC classification number: A61K48/0058 ,  A61K35/76 ,  A61K48/0091 ,  C12N7/00 ,  C12N15/86 ,  C12N15/8616 ,  C12N2310/14 ,  C12N2310/17 ,  C12N2750/14143 ,  C12N2830/38

Abstract: The present invention relates to nucleic acid molecules containing spacers that can be packaged into viral particles and methods of producing them. In a first aspect, the invention features a nucleic acid molecule including a first spacer (SSI); a first inverted terminal repeat (ITR1); a cloning site (CS); a second inverted terminal repeat (ITR2); and a second spacer (SS2), such as a eukaryotic spacer; operably linked to each other in a 5′-to-3′ direction as: SS1-ITR1-CS-ITR2-SS2. In an embodiment, the invention features a vector comprising any of the above-described nucleic acid molecules. In another aspect, the invention features a plurality of viral particles including the nucleic acid molecule. The invention further includes a host cell including any of the above-described vectors.

公开(公告)号：US20180030453A1

公开(公告)日：2018-02-01

申请号：US15551659

申请日：2016-02-18

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Stanislav S. ZAKHARENKO ,  Jay A. BLUNDON

IPC: C12N15/113 ,  G09B5/00 ,  G09B19/00 ,  A61K31/4545 ,  A61K31/416

Abstract: The invention is directed to a method for improving learning and/or memory (e.g., auditory, visual, somatosensory or motor) in adults and children of an age which is beyond the early critical period for learning, said method comprising inhibiting (i) ecto-5′-nucleotidase (Nt5e, aka CD73) or (ii) A1 adenosine receptor (A1R, aka Adora1) expression or function in the brain. The invention is also directed to a method for treating learning and memory defects and neurological diseases associated with an abnormal auditory, visual, or somatosensory perception by inhibiting Nt5e or A1R expression or function in the brain.

公开(公告)号：US20170107491A1

公开(公告)日：2017-04-20

申请号：US15337854

申请日：2016-10-28

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. ,  NATIONAL UNIVERSITY OF SINGAPORE

Inventor： Dario Campana ,  Yu-Hsiang Chang

IPC: C12N5/0783 ,  A61K35/17 ,  C07K14/725 ,  C12N5/00 ,  C07K14/705

CPC classification number: C12N5/0646 ,  A61K35/17 ,  A61K38/00 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/7056 ,  C07K2319/00 ,  C07K2319/70 ,  C12N5/0087 ,  C12N2510/00

Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompansses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.

公开(公告)号：US20170073638A1

公开(公告)日：2017-03-16

申请号：US15309362

申请日：2015-05-14

Applicant: National University of Singapore ,  St. Jude Children's Research Hospital, Inc.

Inventor： Dario CAMPANA ,  David SHOOK ,  Masaru IMAMURA

IPC: C12N5/0783 ,  C07K14/705 ,  C07K14/54 ,  A61K38/20 ,  A61K35/17

CPC classification number: C12N5/0646 ,  A61K35/17 ,  A61K38/2013 ,  A61K38/2086 ,  C07K14/5443 ,  C07K14/70517 ,  C07K2319/03 ,  C12N5/0006 ,  C12N15/62 ,  C12N2501/2315 ,  C12N2510/00

Abstract: The present invention provides, in certain aspects, a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15), and methods for producing such cells. The invention further provides methods of using a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15) to treat cancer in a subject or to enhance expansion and/or survival of NK cells.

Abstract translation: 本发明在某些方面提供表达白细胞介素-15（IL-15）的全部或功能部分的天然杀伤（NK）细胞，以及用于制备这些细胞的方法。 本发明还提供了使用表达白细胞介素-15（IL-15）的全部或功能部分以治疗受试者的癌症或增强NK细胞的扩增和/或存活的自然杀伤（NK）细胞的方法。

公开(公告)号：US20160324874A1

公开(公告)日：2016-11-10

申请号：US15031426

申请日：2014-10-24

Applicant: St. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

Inventor： Wai-Hang LEUNG ,  Wing LEUNG

IPC: A61K31/585 ,  A61K31/58

CPC classification number: A61K31/585 ,  A61K31/56 ,  A61K31/58

Abstract: The invention is directed to the use of Retinoid X Receptor-gamma (RXR-gamma) agonists and Retinoid X Receptor-alpha (RXR-alpha) antagonists in treatment of cancer.

Abstract translation: 本发明涉及视黄酸X受体-γ（RXR-γ）激动剂和类视黄醇X受体-α（RXR-α）拮抗剂在癌症治疗中的用途。

公开(公告)号：US20160000828A1

公开(公告)日：2016-01-07

申请号：US14764070

申请日：2014-01-28

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. ,  NATIONAL UNIVERSITY OF SINGAPORE

Inventor： Dario CAMPANA ,  Yu-Hsiang CHANG

IPC: A61K35/17

CPC classification number: C12N5/0646 ,  A61K35/17 ,  A61K38/00 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/7056 ,  C07K2319/00 ,  C07K2319/70 ,  C12N5/0087 ,  C12N2510/00

Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for the use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.

Abstract translation: 本发明提供了包含NKG2D，DAP10和CD3ζ的嵌合受体。 还公开了包含该嵌合受体的组合物和用于制备和使用其以增强NK细胞的细胞毒性和抗肿瘤能力的方法。 本发明还包括在用于治疗癌症和其它增殖性疾病以及感染性疾病的方法中使用NKG2D-DAP10-CD3ζ多肽，载体和细胞的方法。

公开(公告)号：US09005629B2

公开(公告)日：2015-04-14

申请号：US13679485

申请日：2012-11-16

Applicant: The Johns Hopkins University ,  St. Jude Children's Research Hospital Inc.

Inventor： Drew M Pardoll ,  Ching-Tai Huang ,  Jonathan Powell ,  Charles Drake ,  Dario A Vignali ,  Creg J Workman

IPC: A61K39/00 ,  A61K39/38 ,  A61K39/395 ,  A01K67/027 ,  C07K14/705 ,  C07K16/28 ,  C12N5/0783 ,  C07K16/42 ,  A61K35/12

CPC classification number: C07K16/2803 ,  A01K67/0271 ,  A01K67/0276 ,  A01K2267/0381 ,  A61K39/0011 ,  A61K39/3955 ,  A61K39/39558 ,  A61K2035/122 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/5156 ,  A61K2039/55516 ,  C07K14/70503 ,  C07K16/18 ,  C07K16/42 ,  C12N5/0636 ,  C12N2501/599 ,  C12N2510/00 ,  C12N2799/027

Abstract: Mammals with cancer are treated with an antibody which specifically binds to CD223 protein and inhibits negative T cell regulatory function of CD223. The mammal may be a human. The antibody may be a monoclonal antibody. The amount of the antibody administered may be sufficient to enhance an immune T cell response to the cancer.

Abstract translation: 具有癌症的哺乳动物用特异性结合CD223蛋白的抗体治疗，并抑制CD223的负T细胞调节功能。 哺乳动物可能是一个人。 抗体可以是单克隆抗体。 施用的抗体的量可以足以增强对癌症的免疫T细胞应答。

公开(公告)号：US20130266551A1

公开(公告)日：2013-10-10

申请号：US13826258

申请日：2013-03-14

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： DARIO CAMPANA ,  CHIHAYA IMAI

IPC: C07K16/28

CPC classification number: C07K16/2896 ,  A61K39/0011 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/2866 ,  C07K16/2878 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C12N5/0646 ,  C12N2501/2302 ,  C12N2501/2315 ,  C12N2501/599 ,  C12N2502/99 ,  C12N2510/00

Abstract: The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use.

Abstract translation: 本发明涉及能够表达原始和共刺激途径的嵌合受体，从而允许激活共刺激途径而不与天然配体结合。 受体的细胞质结构域含有4-1BB信号结构域的一部分。 本发明的实施方案涉及编码受体的多核苷酸，编码嵌合受体的载体和宿主细胞，特别包括T细胞和天然杀伤（NK）细胞及其使用方法。